Keyphrases
Anticancer Drugs
100%
Pharmacokinetics
100%
Antitumor Activity
100%
Novel Combinations
100%
Adverse Events
80%
Phase I Trial
60%
Hyperglycemia
60%
Blood Samples
40%
Treatment Options
40%
Monotherapy
40%
Olaparib
40%
Pre-screening
40%
Target Engagement
40%
Targeted Inhibitors
40%
Anticancer Therapy
20%
Diarrhea
20%
Paclitaxel
20%
Safety Assessment
20%
Cytotoxic Agents
20%
Phosphate
20%
Safety Profile
20%
PARP Inhibitor (PARPi)
20%
Computed Tomography
20%
Carboplatin
20%
Vital Signs
20%
Pharmacokinetic Profile
20%
Hematology
20%
Dosing Regimen
20%
Anticancer Treatment
20%
Cell Signaling Pathways
20%
Physiological Role
20%
AKT1
20%
PI3K Inhibitor
20%
Personalized Treatment
20%
Targeted Agents
20%
Bone Marrow Suppression
20%
Clinical Chemistry
20%
PI3K-Akt Pathway
20%
Genetic Aberrations
20%
One Fits All
20%
Cytotoxic Therapy
20%
Cytotoxic Chemotherapy
20%
FGFR Inhibitor
20%
Patient Tumor
20%
MEK Pathway
20%
Laboratory Assessment
20%
High Response Rate
20%
Targeted Compounds
20%
Ocular Toxicity
20%
AKT Inhibitor
20%
Radiological Assessment
20%
2-cycles
20%
Target Pathways
20%
Pharmacology, Toxicology and Pharmaceutical Science
Anticarcinogen
100%
Neoplasm
100%
Pharmacokinetics
100%
Adverse Event
66%
Phase I Trials
50%
Hyperglycemia
50%
Cytotoxic Chemotherapy
33%
Malignant Neoplasm
33%
Biological Marker
33%
Olaparib
33%
Monotherapy
33%
Clinical Study
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
16%
Paclitaxel
16%
Diarrhea
16%
Eye Toxicity
16%
Carboplatin
16%
Bone Marrow Suppression
16%
Protein Kinase B
16%
Cytotoxic Agent
16%